🇺🇸 FDA
Pipeline program

2.0mg Buprenorphine/0.5mg Naloxone

RB-US-08-0003

Approved small_molecule completed

Quick answer

2.0mg Buprenorphine/0.5mg Naloxone for Hepatic Failure is a Approved program (small_molecule) at Indivior Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Indivior Pharmaceuticals
Indication
Hepatic Failure
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials